Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039383 · ClinicalTrials.gov registry record
A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 79
- Enrollment target
NCT07039383 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 79 participants.
The verdict
NCT07039383 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel). Five centers in the United States were included for the study. The date of the initial tisa-cel infusion was defined as the index date. A baseline period from ALL diagnosis to the index date was used to capture patient characteristics including demographics, and disease and treatment history. The study period, defined as the period from tisa-cel infusion to the end of follow-up date, i.e. the last contact date on medical charts or death, whichever was earlier, was used to capture the clinical outcomes of tisa-cel among ALL patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07039383
The ClinicalTrials.gov registry entry for NCT07039383 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07039383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07039383 about?
NCT07039383 is a clinical study titled "A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients". This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel). Five centers in the United States were included for the study. The date of the i...
What is the current status of trial NCT07039383?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2023-03-01. Estimated completion is 2024-06-18.
Who is sponsoring clinical trial NCT07039383?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.